Jazz Pharmaceuticals
JAZZ
406 hedge funds and large institutions have $6.55B invested in Jazz Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 162 increasing their positions, 137 reducing their positions, and 54 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 137
18% more call options, than puts
Call options by funds: $35.5M | Put options by funds: $30.1M
1.42% more ownership
Funds ownership: 88.93% → 90.35% (+1.4%)
2% less funds holding
Funds holding: 416 → 406 (-10)
9% less capital invested
Capital invested by funds: $7.16B → $6.55B (-$612M)
19% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 54
57% less funds holding in top 10
Funds holding in top 10: 7 → 3 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$79.6M |
| 2 |
Renaissance Technologies
New York
|
+$75.3M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$37M |
| 4 |
Goldman Sachs
New York
|
+$36.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$29.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$139M |
| 2 |
Two Sigma Advisers
New York
|
-$48.4M |
| 3 |
Bank of New York Mellon
New York
|
-$25.3M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$23.7M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$20.2M |
JAZZ Hedge Fund Activity: Q3 2019 in Review
406 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2019, worth a combined $6.55B — down 8.5% from $7.16B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of JAZZ and 44 opened new positions — a net loss of 10 holders — while 137 trimmed existing stakes and 162 added.
The largest buyer was LSV Asset Management, adding an estimated $79.6M. The largest seller was Fidelity Investments, cutting an estimated $139M.
- 406 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2019, down from 416 in Q2 2019.
- Funds reported $6.55B of Jazz Pharmaceuticals stock for Q3 2019, down 8.5% quarter-over-quarter.
- 44 funds opened new Jazz Pharmaceuticals positions in Q3 2019 and 54 closed out, a net change of -10 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2019 was LSV Asset Management, an estimated $79.6M added.
- The largest Jazz Pharmaceuticals seller in Q3 2019 was Fidelity Investments, an estimated $139M sold.
Based on aggregated 13F filings for Q3 2019.